What is Akt?
Akt (also called protein kinase B / PKB) is a serine/threonine kinase positioned downstream of PI3K in the PI3K-Akt-mTOR signalling cascade. Akt phosphorylation is the gatekeeping step for cell survival, growth, and metabolic responses; engages downstream targets including eNOS, glycogen synthase kinase 3, BAD, and FOXO transcription factors.
What the research literature says
Akt is a family of three closely related kinases (Akt1, Akt2, Akt3). Activation is a two-step process: PI3K generates the membrane lipid PIP3, which recruits Akt to the inner plasma-membrane leaflet via its pleckstrin-homology domain, and a pair of upstream kinases (PDK1 on Thr308 and mTORC2 on Ser473) then phosphorylate Akt into its active form.
In peptide-research contexts the cascade is most often described as VEGFR2 → PI3K → Akt → eNOS. The Hsieh BPC-157 work documented this cascade in vascular endothelial cell culture (PMID 27847966), with the Sikiric nitric-oxide-system review consolidating the downstream NO-output framework (PMID 23755725). The 2024 Sikiric comprehensive review integrates Akt-axis findings across gastric, vascular, and cytoprotective models (PMID 38980576).
The detailed coverage of Akt signalling is in the Akt signalling glossary entry.
Why this matters in research context
Akt matters in peptide-research contexts as the central convergent signalling node downstream of multiple receptor pathways. Researchers studying the cellular effects of receptor-engaging peptides should expect Akt phosphorylation as a key intermediate readout; pharmacological Akt inhibition (with MK-2206 or related selective inhibitors) is a standard tool for confirming pathway-causality in mechanism studies. The receptor inhibitors LY294002 (upstream of Akt, blocking PI3K) and wortmannin (same upstream target) are the alternative pharmacological tools for confirming the broader cascade. When inhibitor pre-treatment abolishes both Akt phosphorylation and the downstream functional outcome, the cascade is implicated as causal rather than coincidental in the observed pharmacology.
Related compounds
- BPC-157 10mg — VEGFR2-Akt-eNOS cascade
- TB-500 10mg — ILK-PI3K-Akt arm
Related research questions
References
- Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl) 2017;95(3):323-333. [PMID 27847966]
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des 2014;20(7):1126-1135. [PMID 23755725]
- Sikiric P et al. New studies with stable gastric pentadecapeptide protecting gastrointestinal tract. Inflammopharmacology 2024;32(5):3119-3161. [PMID 38980576]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Every compound in the Ronin catalog is sold strictly for laboratory and research use only.